KR102680786B1 - Cns 병태의 치료 - Google Patents

Cns 병태의 치료 Download PDF

Info

Publication number
KR102680786B1
KR102680786B1 KR1020207004753A KR20207004753A KR102680786B1 KR 102680786 B1 KR102680786 B1 KR 102680786B1 KR 1020207004753 A KR1020207004753 A KR 1020207004753A KR 20207004753 A KR20207004753 A KR 20207004753A KR 102680786 B1 KR102680786 B1 KR 102680786B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
syndrome
day
benzyl
hydroxypiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207004753A
Other languages
English (en)
Korean (ko)
Other versions
KR20200046022A (ko
Inventor
도시야 니시
신이치 곤도
Original Assignee
다케다 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 야쿠힌 고교 가부시키가이샤 filed Critical 다케다 야쿠힌 고교 가부시키가이샤
Publication of KR20200046022A publication Critical patent/KR20200046022A/ko
Application granted granted Critical
Publication of KR102680786B1 publication Critical patent/KR102680786B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020207004753A 2017-08-31 2018-08-30 Cns 병태의 치료 Active KR102680786B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553070P 2017-08-31 2017-08-31
US62/553,070 2017-08-31
PCT/JP2018/032949 WO2019045121A1 (en) 2017-08-31 2018-08-30 TREATMENT OF CNS DISEASES

Publications (2)

Publication Number Publication Date
KR20200046022A KR20200046022A (ko) 2020-05-06
KR102680786B1 true KR102680786B1 (ko) 2024-07-02

Family

ID=63722720

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207004753A Active KR102680786B1 (ko) 2017-08-31 2018-08-30 Cns 병태의 치료

Country Status (7)

Country Link
US (4) US11285139B2 (enExample)
EP (1) EP3675852A1 (enExample)
JP (2) JP7196157B2 (enExample)
KR (1) KR102680786B1 (enExample)
CN (2) CN111065394B (enExample)
MX (1) MX2020001732A (enExample)
WO (1) WO2019045121A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
CA2918735C (en) 2013-07-19 2023-08-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
CN111432812A (zh) 2017-11-14 2020-07-17 爱思开生物制药株式会社 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途
WO2020021372A1 (en) * 2018-07-24 2020-01-30 Zenvision Pharma Llp Nasal drug delivery system of brivaracetam or salt thereof thereof
GB2580881A (en) * 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物
CN114746408B (zh) * 2019-12-02 2025-02-14 豪夫迈·罗氏有限公司 炔基-(杂芳基)-甲酰胺hcn1抑制剂
GB2597312A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597285A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
US20240197704A1 (en) * 2021-04-09 2024-06-20 Johns Hopkins University Treatment methods and compositions comprising perampanel
CN115487144A (zh) * 2021-06-18 2022-12-20 北京万全德众医药生物技术有限公司 一种卢非酰胺的口服液制备方法
WO2023175591A1 (en) * 2022-03-18 2023-09-21 Takeda Pharmaceutical Company Limited Methods of treating neurological diseases
WO2024100531A1 (en) * 2022-11-07 2024-05-16 Takeda Pharmaceutical Company Limited Method of treating seizure disorders
WO2025126159A1 (en) * 2023-12-15 2025-06-19 Takeda Pharmaceutical Company Limited A method for treating a neurological disease in a recreational drug user
WO2025257799A1 (en) * 2024-06-14 2025-12-18 Takeda Pharmaceutical Company Limited Methods of treating dravet syndrome
CN121550436B (zh) * 2026-01-23 2026-05-12 四川大学华西医院 组合物及联合用药方式

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648079B2 (en) 2011-10-07 2014-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds
EA029056B1 (ru) 2012-12-11 2018-02-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
WO2014163161A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
JP6807322B2 (ja) 2015-10-16 2021-01-06 武田薬品工業株式会社 複素環化合物の製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Neurobiology of Disease, 92, pp.72-89(2016) 1부.*

Also Published As

Publication number Publication date
CN111065394A (zh) 2020-04-24
US20220168294A1 (en) 2022-06-02
CA3073925A1 (en) 2019-03-07
MX2020001732A (es) 2020-03-20
WO2019045121A1 (en) 2019-03-07
JP7196157B2 (ja) 2022-12-26
CN116370475A (zh) 2023-07-04
JP2023027267A (ja) 2023-03-01
US11285139B2 (en) 2022-03-29
JP2020532508A (ja) 2020-11-12
CN111065394B (zh) 2023-03-31
EP3675852A1 (en) 2020-07-08
US20250281477A1 (en) 2025-09-11
US20230087903A1 (en) 2023-03-23
KR20200046022A (ko) 2020-05-06
JP7469445B2 (ja) 2024-04-16
US20200306238A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
JP7469445B2 (ja) Ｃｎｓ状態の治療
EP3340971B1 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
JP4249415B2 (ja) Ｃｎｓ疾患の治療のためのピロリジンアセトアミド誘導体単体又は組み合わせ物
Kutlu et al. Levetiracetam monotherapy for late poststroke seizures in the elderly
Silberstein et al. Oxcarbazepine in migraine headache: a double-blind, randomized, placebo-controlled study
US20220133652A1 (en) A formulation for improving seizure control
BR112020002077A2 (pt) usos combinados de lasmiditan e de um antagonista de cgrp na preparação de medicamentos para tratamento de enxaqueca e outras dores de cabeça
TWI826514B (zh) 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
US11723890B2 (en) Methods of treatment using an mTORC1 modulator
CN110214146B (zh) 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
US20190321351A1 (en) Methods for treating neurological conditions and exposure to nerve agents
Yeo et al. Oral agents for the management of agitation and agitated delirium in critically ill patients
Wang et al. Efficacy and tolerability of perampanel as add‐on therapy in Dravet syndrome: A prospective real‐world study
US8222278B2 (en) Treatment of attention-deficit/hyperactivity disorder
WO2025207826A1 (en) Methods of treatment of neurological disorders
HK40113588A (en) Methods of treating lennox-gastaut syndrome using fenfluramine

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-5-5-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000